Pitolisant (Wakix)

What it treats

Pitolisant is approved by the U.S. Food and Drug Administration for:

• Excessive daytime sleepiness in adults with narcolepsy.
• Cataplexy in adults with narcolepsy.

Cataplexy is the sudden loss of muscle tone triggered by strong emotion in narcolepsy type 1. Pitolisant reduces cataplexy frequency in patients who have it, which is an unusual dual benefit for a single medication.

How it works

Pitolisant boosts the brain's own release of histamine, which is one of the neurotransmitters that maintain wakefulness. In the brain, histamine H3 receptors act as brakes on histamine release. Pitolisant blocks those brakes (as an inverse agonist at H3), so more histamine is released, and wakefulness improves.

That mechanism is separate from dopamine and norepinephrine. It's also why pitolisant isn't a controlled substance: it doesn't act on the reward-related dopamine pathways that give traditional stimulants their misuse potential.

Receptor mechanism (detail)

Pitolisant is a selective histamine H3 receptor inverse agonist and antagonist. H3 receptors are presynaptic autoreceptors that inhibit histamine release. Blocking them increases histamine release, which boosts wakefulness. Pitolisant also modestly influences acetylcholine and dopamine release indirectly through the histamine system. It doesn't directly bind DAT or NET, which is why it isn't a controlled substance and doesn't produce the peripheral or subjective effects of dopamine-releasing stimulants.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual.

Starting: 8.9 mg once each morning for the first week. Week 2: 17.8 mg once each morning. From week 3: 35.6 mg once each morning (target). Dose adjustments for hepatic impairment, some CYP2D6 poor metabolizers, or coadministration with strong CYP2D6 inhibitors.

Half-life is about 20 hours, and steady-state effect builds over 2 to 3 weeks. That is longer than most wake-promoting drugs and is why titration is stepwise.

Safety monitoring

• QTc interval. Baseline and periodic ECG in patients at risk for QT prolongation, or with other QT-prolonging medications.
• Heart rate at baseline and periodically.
• Not a controlled substance, which is a distinguishing feature from all other approved wake-promoting agents.
• Hormonal contraceptive interaction. Pitolisant can reduce oral contraceptive effectiveness; non-hormonal backup during use and for 21 days after stopping.
• Hepatic impairment. Dose reduction needed in moderate impairment; avoid in severe.
• Do not combine with strong CYP2D6 inhibitors without dose adjustment.

What to expect

Common side effects

• Headache, the most common.
• Insomnia (paradoxical, because of the wake-promoting effect if dosed too late).
• Nausea.
• Anxiety.
• Upper respiratory infection.
• Musculoskeletal pain.

If a side effect is bothersome or persistent, that's a conversation for the prescriber.

Serious side effects and warnings

• QT prolongation. Modest but real. Combined with other QT-prolonging medications, this can become clinically important.
• Psychiatric symptoms. Anxiety, insomnia, depression, and, rarely, hallucinations or suicidal thoughts.
• Hypersensitivity reactions, rare.
• Contraceptive failure. Pitolisant reduces hormonal contraceptive effectiveness during use and for 21 days after stopping.

Sexual side effects

Pitolisant isn't a notable cause of sexual side effects. If a change occurs, mention it to a prescriber.

Weight, appetite, and sleep

Pitolisant is generally weight-neutral. Insomnia can occur if dosed too late in the day, so morning dosing is standard. The long half-life means late-day dosing is more likely to affect sleep than with shorter-acting wake-promoting agents.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual. The right dose is a decision for a prescriber.

Pitolisant comes as tablets in 4.45 mg and 17.8 mg strengths. Titration is stepwise over 3 weeks.

Missed doses and interactions

If a morning dose is missed and it's still early, take it. If it's late, skip and resume the next day.

Pitolisant is metabolized largely by CYP2D6 and CYP3A4. Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) raise levels and require dose reduction. Strong CYP3A4 inducers (rifampin, some anticonvulsants) can reduce levels and require dose adjustment. It also modestly induces CYP3A4, which is why it can reduce oral contraceptive effectiveness.

Give every prescriber and pharmacist the full medication list.

Stopping and tapering

Pitolisant doesn't require a formal taper. Sleepiness and cataplexy will likely return over days to weeks if not otherwise treated.

Pregnancy and breastfeeding

Data are limited. Animal studies suggest possible risk. Individual circumstances matter and the decision belongs with a clinician. Anyone pregnant, planning a pregnancy, or breastfeeding should discuss it with their prescriber. Contraceptive planning matters given the effect on hormonal contraception.

Cost and generic availability

Pitolisant is a newer, branded medication and is not yet available as a generic. Cost is substantial. Insurance coverage varies. The manufacturer offers copay assistance in some cases.

Common questions

Is pitolisant a stimulant? No. It works through histamine, not through dopamine or norepinephrine. That is why it isn't a controlled substance and doesn't produce the subjective feel of amphetamines or methylphenidate.

Why is it not controlled? Because it doesn't act on the dopamine reward pathways that give traditional stimulants their misuse potential. It's the first FDA-approved wake-promoting agent for narcolepsy that isn't a controlled substance.

How long until it works? Unlike most wake-promoting drugs, pitolisant builds up over 2 to 3 weeks. Effect on sleepiness usually shows by week 3 at target dose; effect on cataplexy over 4 to 8 weeks.

Does it interact with birth control pills? Yes. Pitolisant reduces hormonal contraceptive effectiveness. Use a non-hormonal backup during use and for 21 days after stopping.

Questions to ask your prescriber

• Why pitolisant over other wake-promoting agents for me?
• How long until I should expect to feel a difference?
• What ECG or blood pressure checks do we need?
• If I'm on hormonal contraception, what should I use for backup?
• Which of my other medications interact with pitolisant?

Sources

This guide draws on current prescribing information and public health references and current as of June 8, 2026. It is reviewed for clinical accuracy and updated as guidance changes.

• U.S. Food and Drug Administration. Pitolisant (Wakix) prescribing information.
• MedlinePlus, U.S. National Library of Medicine. Pitolisant.
• American Academy of Sleep Medicine. Clinical Practice Guideline for the Treatment of Central Disorders of Hypersomnolence.
• National Institute of Neurological Disorders and Stroke. Narcolepsy information page.